These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

85 related items for PubMed ID: 16244087

  • 1. Cost effectiveness of inhaled steroid withdrawal in outpatients with chronic obstructive pulmonary disease.
    van der Palen J, Monninkhof E, van der Valk P, Sullivan SD, Veenstra DL.
    Thorax; 2006 Jan; 61(1):29-33. PubMed ID: 16244087
    [Abstract] [Full Text] [Related]

  • 2. Withdrawal of fluticasone propionate from combined salmeterol/fluticasone treatment in patients with COPD causes immediate and sustained disease deterioration: a randomised controlled trial.
    Wouters EF, Postma DS, Fokkens B, Hop WC, Prins J, Kuipers AF, Pasma HR, Hensing CA, Creutzberg EC, COSMIC (COPD and Seretide: a Multi-Center Intervention and Characterization) Study Group.
    Thorax; 2005 Jun; 60(6):480-7. PubMed ID: 15923248
    [Abstract] [Full Text] [Related]

  • 3. Cost effectiveness of therapy with combinations of long acting bronchodilators and inhaled steroids for treatment of COPD.
    Najafzadeh M, Marra CA, Sadatsafavi M, Aaron SD, Sullivan SD, Vandemheen KL, Jones PW, Fitzgerald JM.
    Thorax; 2008 Nov; 63(11):962-7. PubMed ID: 18621985
    [Abstract] [Full Text] [Related]

  • 4. Effect of discontinuation of inhaled corticosteroids in patients with chronic obstructive pulmonary disease: the COPE study.
    van der Valk P, Monninkhof E, van der Palen J, Zielhuis G, van Herwaarden C.
    Am J Respir Crit Care Med; 2002 Nov 15; 166(10):1358-63. PubMed ID: 12406823
    [Abstract] [Full Text] [Related]

  • 5. Cost-effectiveness of salmeterol, fluticasone, and combination therapy for COPD.
    Oba Y.
    Am J Manag Care; 2009 Apr 15; 15(4):226-32. PubMed ID: 19355795
    [Abstract] [Full Text] [Related]

  • 6. Estimating the cost-effectiveness of fluticasone propionate for treating chronic obstructive pulmonary disease in the presence of missing data.
    Briggs AH, Lozano-Ortega G, Spencer S, Bale G, Spencer MD, Burge PS.
    Value Health; 2006 Apr 15; 9(4):227-35. PubMed ID: 16903992
    [Abstract] [Full Text] [Related]

  • 7. Cost-effectiveness of fluticasone propionate/salmeterol (500/50 microg) in the treatment of COPD.
    Earnshaw SR, Wilson MR, Dalal AA, Chambers MG, Jhingran P, Stanford R, Mapel DW.
    Respir Med; 2009 Jan 15; 103(1):12-21. PubMed ID: 19010652
    [Abstract] [Full Text] [Related]

  • 8. Is treatment with ICS and LABA cost-effective for COPD? Multinational economic analysis of the TORCH study.
    Briggs AH, Glick HA, Lozano-Ortega G, Spencer M, Calverley PM, Jones PW, Vestbo J, TOwards a Revolution in COPD Health (TORCH) investigators.
    Eur Respir J; 2010 Mar 15; 35(3):532-9. PubMed ID: 19717476
    [Abstract] [Full Text] [Related]

  • 9. Bronchodilator reversibility, airway eosinophilia and anti-inflammatory effects of inhaled fluticasone in COPD are not related.
    Reid DW, Wen Y, Johns DP, Williams TJ, Ward C, Walters EH.
    Respirology; 2008 Nov 15; 13(6):799-809. PubMed ID: 18811878
    [Abstract] [Full Text] [Related]

  • 10. Economic assessment of initial maintenance therapy for chronic obstructive pulmonary disease.
    Akazawa M, Hayflinger DC, Stanford RH, Blanchette CM.
    Am J Manag Care; 2008 Jul 15; 14(7):438-48. PubMed ID: 18611095
    [Abstract] [Full Text] [Related]

  • 11. Pneumonia risk in COPD patients receiving inhaled corticosteroids alone or in combination: TORCH study results.
    Crim C, Calverley PM, Anderson JA, Celli B, Ferguson GT, Jenkins C, Jones PW, Willits LR, Yates JC, Vestbo J.
    Eur Respir J; 2009 Sep 15; 34(3):641-7. PubMed ID: 19443528
    [Abstract] [Full Text] [Related]

  • 12. Comparison of hospitalizations, emergency department visits, and costs in a historical cohort of Texas Medicaid patients with chronic obstructive pulmonary disease, by initial medication regimen.
    Rascati KL, Akazawa M, Johnsrud M, Stanford RH, Blanchette CM.
    Clin Ther; 2007 Jun 15; 29(6):1203-13. PubMed ID: 17692734
    [Abstract] [Full Text] [Related]

  • 13. Benefits and risks of adjunctive inhaled corticosteroids in chronic obstructive pulmonary disease: a meta-analysis.
    Sobieraj DM, White CM, Coleman CI.
    Clin Ther; 2008 Aug 15; 30(8):1416-25. PubMed ID: 18803985
    [Abstract] [Full Text] [Related]

  • 14. The presence of emphysema does not affect the systemic bioactivity of inhaled fluticasone in severe chronic obstructive pulmonary disease.
    Lee DK, Lipworth BJ.
    Br J Clin Pharmacol; 2004 Apr 15; 57(4):388-92. PubMed ID: 15025735
    [Abstract] [Full Text] [Related]

  • 15. Cost-effectiveness of fluticasone propionate in the treatment of chronic obstructive pulmonary disease: a double-blind randomized, placebo-controlled trial.
    Ayres JG, Price MJ, Efthimiou J.
    Respir Med; 2003 Mar 15; 97(3):212-20. PubMed ID: 12645827
    [Abstract] [Full Text] [Related]

  • 16. The effects of inhaled fluticasone on airway inflammation in chronic obstructive pulmonary disease: a double-blind, placebo-controlled biopsy study.
    Hattotuwa KL, Gizycki MJ, Ansari TW, Jeffery PK, Barnes NC.
    Am J Respir Crit Care Med; 2002 Jun 15; 165(12):1592-6. PubMed ID: 12070058
    [Abstract] [Full Text] [Related]

  • 17. Risk of hospitalizations/emergency department visits and treatment costs associated with initial maintenance therapy using fluticasone propionate 500 microg/salmeterol 50 microg compared with ipratropium for chronic obstructive pulmonary disease in older adults.
    Blanchette CM, Akazawa M, Dalal A, Simoni-Wastila L.
    Am J Geriatr Pharmacother; 2008 Aug 15; 6(3):138-46. PubMed ID: 18775388
    [Abstract] [Full Text] [Related]

  • 18. Pharmacologic treatments for chronic obstructive pulmonary disease: a mixed-treatment comparison meta-analysis.
    Baker WL, Baker EL, Coleman CI.
    Pharmacotherapy; 2009 Aug 15; 29(8):891-905. PubMed ID: 19637942
    [Abstract] [Full Text] [Related]

  • 19. Cost-effectiveness of inhaled corticosteroids for chronic obstructive pulmonary disease according to disease severity.
    Sin DD, Golmohammadi K, Jacobs P.
    Am J Med; 2004 Mar 01; 116(5):325-31. PubMed ID: 14984818
    [Abstract] [Full Text] [Related]

  • 20. Effect of fluticasone propionate/salmeterol (250/50 microg) or salmeterol (50 microg) on COPD exacerbations.
    Ferguson GT, Anzueto A, Fei R, Emmett A, Knobil K, Kalberg C.
    Respir Med; 2008 Aug 01; 102(8):1099-108. PubMed ID: 18614347
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 5.